Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

類似資料

• Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
  著者:: Loke, Lydia, 等
  出版事項: (2020)
• Healthcare in Singapore: the present and future
  著者:: How, Choon How, 等
  出版事項: (2014)
• Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3
  著者:: Kato, Terufumi, 等
  出版事項: (2015)
• Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases
  著者:: ZHANG, YALEI, 等
  出版事項: (2014)
• Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
  著者:: Aziz, Mohamed Ismail Abdul, 等
  出版事項: (2018)